Headquartered in Deerfield, Illinois, Baxter International Inc. BAX is a global medical products and services company. The company’s Hospital Products business manufactures products used in the delivery of fluids and drugs to patients. Renal portfolio is mainly for patients with kidney failure/disease and their healthcare providers.

Currently, Baxter International has a Zacks Rank #3 (Hold) but that could change following its first quarter 2017 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.) We have highlighted some of the key details from the just-released announcement below:

Earnings: Baxter’s adjusted earnings of 58 cents per share beat the Zacks Consensus Estimate of 51 cents and increased by 22 cents from the year-ago quarter.

Revenues: Baxter posted sales of $2.47 billion, marginally beating the Zacks Consensus Estimate for revenues of $2.43 billion. At constant currency (cc), revenues increased almost 5% on a year-over-year basis.

Key Stats: Hospital products sales increased 7% at cc, while renal products inched up 1% from the year-ago quarter.

Baxter International Inc. Price and EPS Surprise

Baxter International Inc. Price and EPS Surprise | Baxter International Inc. Quote

Major Factors:  Hospital Products sales in the quarter were driven by solid sales in the U.S. for IV therapies, IV access sets, and select anesthesia and critical care products. Hospital Sales were also favorably impacted by solid demand for parenteral nutrition therapies and international bio-surgery products.

Renal products sales were driven by solid demand for continuous renal replacement therapies. Increased sales of peritoneal dialysis therapies driven by the continued adoption of the company’s newest Automated Peritoneal Dialysis (APD) cyclers also enhanced the renal products sales in the quarter.

Stock Price:Shares have risen roughly 13% over the past 3 months, while the Zacks categorized Medical Products sub industry has gained 7.6% over the same time frame.

Check back later for our full write up on this Baxter International report later!

Zacks’ Best Private Investment Ideas

While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public. 

Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Baxter International Inc. (BAX): Free Stock Analysis Report
 
To read this article on Zacks.com click here.